IL122630A - Polymorphic form of doxazosin mesylate (form III) - Google Patents

Polymorphic form of doxazosin mesylate (form III)

Info

Publication number
IL122630A
IL122630A IL12263097A IL12263097A IL122630A IL 122630 A IL122630 A IL 122630A IL 12263097 A IL12263097 A IL 12263097A IL 12263097 A IL12263097 A IL 12263097A IL 122630 A IL122630 A IL 122630A
Authority
IL
Israel
Prior art keywords
doxazosin mesylate
iii
polymorphic
form iii
doxazosin
Prior art date
Application number
IL12263097A
Other languages
English (en)
Other versions
IL122630A0 (en
Original Assignee
Heumann Pharma Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heumann Pharma Gmbh & Co filed Critical Heumann Pharma Gmbh & Co
Publication of IL122630A0 publication Critical patent/IL122630A0/xx
Publication of IL122630A publication Critical patent/IL122630A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
IL12263097A 1996-12-20 1997-12-16 Polymorphic form of doxazosin mesylate (form III) IL122630A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96120603A EP0849266B8 (fr) 1996-12-20 1996-12-20 Nouvelle forme polymorphique de mésylate de doxazosin (forme III)

Publications (2)

Publication Number Publication Date
IL122630A0 IL122630A0 (en) 1998-08-16
IL122630A true IL122630A (en) 2000-02-17

Family

ID=8223531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12263097A IL122630A (en) 1996-12-20 1997-12-16 Polymorphic form of doxazosin mesylate (form III)

Country Status (16)

Country Link
US (1) US6140334A (fr)
EP (1) EP0849266B8 (fr)
JP (1) JP4657393B2 (fr)
KR (1) KR100659927B1 (fr)
AT (1) ATE353892T1 (fr)
AU (1) AU725253B2 (fr)
CA (1) CA2225022C (fr)
DE (1) DE59611417D1 (fr)
DK (1) DK0849266T3 (fr)
ES (1) ES2282997T3 (fr)
HU (1) HU228306B1 (fr)
IL (1) IL122630A (fr)
NZ (1) NZ329406A (fr)
PT (1) PT849266E (fr)
TW (1) TW442484B (fr)
ZA (1) ZA9710634B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849265A1 (fr) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Nouvelle forme polymorphique de mésylate de doxazosin (forme II)
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
ES2164520B1 (es) * 1999-03-16 2003-04-01 Medichem Sa "procedimiento de obtencion del polimorfo a del mesilato de doxazosina"
DE19912063A1 (de) * 1999-03-18 2000-09-21 Knoll Ag Neues Verfahren zur Herstellung von Doxazosin-Mesylat in einer als Form A bezeichneten Kristallmodifikation
DE19912573A1 (de) * 1999-03-19 2000-09-21 Knoll Ag Arzneimittel, enthaltend Doxazosin-Mesylat der Kristallmodifikaton D
AU2008339652B2 (en) 2007-12-24 2013-07-04 Cipla Limited Crystalline polymorph of doxazosin mesylate (form IV) and process for preparation thereof
CN109988158A (zh) * 2018-01-03 2019-07-09 合肥立方制药股份有限公司 X晶型、含有x晶型的多沙唑嗪甲磺酸盐及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699054A (en) * 1953-10-09 1955-01-11 Lloyd H Conover Tetracycline
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
DK154082C (da) * 1977-11-05 1989-02-27 Pfizer Analogifremgangsmaade til fremstilling af 4-amino-6,7-dimethoxy-2-(piperazin-1-yl eller homopiperazin-1-yl)-quinazolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
EP0237608B1 (fr) * 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO La forme sigma cristalline, anhydre de 2-[4-(2-furoyl-(2-pipérazin)-1-yl]-4-amino-6,7-diméthoxyquinazoline hydrochlorure et procédé pour sa préparation
EP0459666B1 (fr) * 1990-05-31 1994-11-09 Pfizer Inc. Médicament contre l'impuissance
AU5457694A (en) * 1992-11-04 1994-05-24 Sepracor, Inc. Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
EP0849265A1 (fr) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Nouvelle forme polymorphique de mésylate de doxazosin (forme II)

Also Published As

Publication number Publication date
KR19980064288A (ko) 1998-10-07
PT849266E (pt) 2007-03-30
EP0849266B1 (fr) 2007-02-14
ES2282997T3 (es) 2007-10-16
ATE353892T1 (de) 2007-03-15
JP4657393B2 (ja) 2011-03-23
ZA9710634B (en) 1998-11-11
DK0849266T3 (da) 2007-06-04
EP0849266B8 (fr) 2007-10-03
TW442484B (en) 2001-06-23
AU4844997A (en) 1998-06-25
KR100659927B1 (ko) 2007-04-11
JPH10182641A (ja) 1998-07-07
CA2225022A1 (fr) 1998-06-20
AU725253B2 (en) 2000-10-12
NZ329406A (en) 1998-10-28
DE59611417D1 (de) 2007-03-29
HUP9702477A3 (en) 1999-06-28
HUP9702477A2 (hu) 1999-04-28
CA2225022C (fr) 2008-10-07
IL122630A0 (en) 1998-08-16
HU228306B1 (en) 2013-03-28
US6140334A (en) 2000-10-31
EP0849266A1 (fr) 1998-06-24
HU9702477D0 (en) 1998-03-02

Similar Documents

Publication Publication Date Title
PT1277913E (pt) Navio de perfuração ou conjunto de perfuração semisubmersível multi-actividades
RS50081B (sr) N-(3-etinilfenilamino)-6,7-bis (2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
SE9901462D0 (sv) Novel compound
NO905384L (no) Fremgangsmaate for analyse og styring av vaeskeinnstroemningunder boring.
ITTO940756A0 (it) Procedimento di sintesi vocale mediante concatenazione e parziale so- vrapposizione di forme d'onda.
NO905156L (no) Fremgangsmaate for behandling av borekaks under olje- og gassboring.
IL122630A0 (en) New polymorphic form of doxazosin mesylate (form III)
PL330277A1 (en) Derivatives of 2,4-diaminopyrimidine
ZA9710632B (en) New polymorphic form of doxazosin mesylate (form 1)
PL327733A1 (en) Method of obtaining polyethylene (2,6-naphtalate)
EP1087782A4 (fr) Regulation de tyrosine hydroxylase
FI934748A0 (fi) Foerfarande foer framstaellning av l-5-(2-acetoxipropionylamino)-2,4,6-trijod-isoftalsyradiklorid
IL122631A0 (en) New polymorphic form of doxazosin mesylate (form II)
NO985621D0 (no) FremgangsmÕte og system for boring under anvendelse av skum - skumsammensetning
DE69610793D1 (de) 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
DE69633529D1 (de) Bestimmung des Justierbits
DE69735244D1 (de) Icyp (iodocyanopindolol) rezeptor von säugetieren und dessen anwendungen
AU3404695A (en) Drilling fluid additives for improved shale stabilization, the drilling fluid formed therefrom and method of using same
HUP0100235A3 (en) Method for synthesis of indol and cumaron carboxamid derivatives
DE69805260D1 (de) Mikrowellensynthese von Chinacridonen, 6,13-Dihydrochinacridonen und 6,13-Chinaridonchinonen
GB9700628D0 (en) Chemical synthesis of 1,3-disubstituted quinazolinediones
FR2786486B3 (fr) Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
DE69807578D1 (de) 5-ht1a und 5-ht1d alpha rezeptorantagonisten
張力 Studies on the mechanisms of resistance to pyriproxyfen in the housefly

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired